Navigation Links
CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone

ich provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates and their clinical potential, its plans for its product candidates, its formulation efforts, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, risks associated with developing modified-release formulations of its product candidates, assumptions regarding the mechanism of action of our product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(C) 2007 CombinatoRx, Incorporated. All rights reserved.

Contact

CombinatoRx, Incorporated
Robert Forrester,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
2. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
3. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
4. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
Post Your Comments:
(Date:6/19/2013)... 2013  Omnicell, Inc. (NASDAQ: OMCL ... management solutions and analytics software for healthcare facilities, ... one overall pharmacy equipment vendor in the KLAS ... leading independent healthcare research firm, compared the performance ... annual rankings. Omnicell also received the prestigious "Best ...
(Date:6/19/2013)... SAN FRANCISCO , June 19, 2013  It may ... and possible cure for breast cancer. But these were two ... Endocrine Society,s 95 th Annual Meeting & Expo that ... now some are saying this focus by some of the ... about our culture,s obsession with new research that can not ...
(Date:6/18/2013)... LAVAL, Quebec , June 18, 2013 ... and TSX: VRX) has priced its previously announced public ... Offering, the Company will issue 23,529,412 common shares at ... proceeds of approximately $2.0 billion. The Company will file ... statement on Form S-3 and will make a similar ...
Breaking Medicine Technology:Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Calif., Dec. 27 According to the latest,science, resveratrol ... of,resveratrol plus an array of antioxidant molecules as typically ... rather than resveratrol alone. , ... The most recent study shows mega-dose resveratrol ...
... development and validation of non-animal alternative test methods , ... MatTek Corporation today announced that the ECVAM Scientific Advisory Committee ... Irritation Test (SIT) at its November meeting. ESAC concluded ... for the prediction of skin irritating and non-irritating test substances. ...
Cached Medicine Technology:Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2
(Date:6/19/2013)... 19, 2013 Maui'd Forever , ... to being an effective and cost effective way to ... have partnered up with Tom Barefoot’s Tours providing an ... most of Hawaii’s activities. , They have just released ... get the lowest prices on their Hawaii activities. ...
(Date:6/19/2013)... 2013 According to Transparency Market Research ... Trends, Analysis and Forecast, 2011 – 2017,” the global ... the year 2011 and is expected to reach USD ... 9.7% from 2011 to 2017. Flexible endoscopes formed the ... USD 2,201 million for the year 2011. , Related ...
(Date:6/19/2013)... treating stroke victims has been "time equals brain." That,s because ... a drug that dissolves the stroke-causing blood clot can make ... or lost. , But specific information has been ... drug known as a tissue plasminogen activator, or tPA ... most common type of stroke. , Now, a ...
(Date:6/19/2013)... MAYWOOD, Il. A Loyola University Chicago Niehoff School ... grant to study whether Vitamin D can improve mood ... study also will examine whether vitamin D supplementation can ... their diabetes. The grant is from the National Institute ... , Principal investigator Sue M. Penckofer, PhD, RN and ...
(Date:6/19/2013)... AquaPrint Solutions in Thomson, IL is proud to ... newly-designed Harley Davidson motorcycle gas tank. A couple of weeks ... idea of taking a split tank motorcycle that had been ... into a work of art. , In October of ... seats that had been dipped in a water transfer printer ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
... IL, April 7, 2009) Managing pain in the ICU ... team. However, new reports suggest that taking a comprehensive approach ... in the ICU and even decreasing the incidence of preventable ... CHEST , the peer-reviewed journal of the American College of ...
... for Usability Evaluation of HIT ProvidersCHICAGO, April 7 ... usability of Electronic Health Records (EHRs), User Centric ( ... performance research designed to provide end-users with real data ... the key limiting factors to adoption now is usability. ...
... designed to benefit individuals with autism and their ... America (ASA), the leading grassroots autism organization and ... medical information services, have teamed up to provide ... the spectrum and their families through the MedicAlert(R) ...
... Mass., April 7 Gene Network Sciences, Inc. today ... researcher in the field of genomics-driven drug discovery, co-chair ... be leaving his position as Executive Scientific ... forces with the departing head of Merck oncology, Dr. ...
... with the autoimmune disease systemic lupus erythematosus (SLE) is ... Hormones secreted by the body are therefore believed to ... disease. A new large, population-based observational study found that ... increased risk of SLE, particularly among women who had ...
... Coverage for RetireesJACKSONVILLE, Fla. , April 7 ... health care coverage to retirees, Blue Cross and ... Group Supplement insurance plans. BlueMedicare Group Supplement is ... who are 65 and older.(Logo: ...
Cached Medicine News:Health News:'Pain in the ICU' report suggests comprehensive approach 2Health News:'Pain in the ICU' report suggests comprehensive approach 3Health News:EMRs Put to the Test on Usability 2Health News:EMRs Put to the Test on Usability 3Health News:Autism Society of America Joins MedicAlert Foundation to offer MedicAlert(R) + Safe and Sound(R) - 24-Hour Comprehensive Protection System 2Health News:Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board 2Health News:Gene Network Sciences Names Departing Merck Head of Genetics Eric Schadt as Co-Chair of Scientific Advisory Board 3Health News:Oral contraceptives associated with increased risk of lupus 2Health News:Blue Cross and Blue Shield of Florida Introduces BlueMedicare(SM) Group Supplement 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: